

RESMED INC  
Form 10-Q  
February 06, 2009  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended December 31, 2008

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

001-15317

Commission File Number:

**ResMed Inc.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

98-0152841

(I.R.S. Employer Identification No.)

14040 Danielson St

Poway, CA 92064-6857

Edgar Filing: RESMED INC - Form 10-Q

United States

(Address of principal executive offices)

(858) 746 2400

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

At January 27, 2009, there were 75,881,113 shares of Common Stock (\$0.04 par value) outstanding. This number excludes 5,584,207 shares held by the registrant as treasury shares.

**Table of Contents**

**RESMED INC. AND SUBSIDIARIES**

**INDEX**

<b>Part I</b>	<b><u>Financial Information</u></b>	<b>3</b>
Item 1	<u>Financial Statements</u>	3
	<u>Condensed Consolidated Balance Sheets (Unaudited) as of December 31, 2008 and June 30, 2008</u>	3
	<u>Condensed Consolidated Statements of Income (Unaudited) for the Three Months Ended December 31, 2008 and 2007 and the Six Months Ended December 31, 2008 and 2007</u>	4
	<u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months ended December 31, 2008 and 2007</u>	5
	<u>Notes to the Condensed Consolidated Financial Statements (Unaudited)</u>	6
Item 2	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	27
Item 3	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	41
Item 4	<u>Controls and Procedures</u>	44
<b>Part II</b>	<b><u>Other Information</u></b>	<b>45</b>
Item 1	<u>Legal Proceedings</u>	45
Item 1A	<u>Risk Factors</u>	45
Item 2	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	45
Item 3	<u>Defaults Upon Senior Securities</u>	46
Item 4	<u>Submission of Matters to a Vote of Security Holders</u>	46
Item 5	<u>Other Information</u>	46
Item 6	<u>Exhibits</u>	47
	<u>Signatures</u>	48

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

Condensed Consolidated Balance Sheets (Unaudited)

(In US\$ thousands, except share and per share data)

	December 31, 2008	June 30, 2008
<b>ASSETS</b>		
<u>Current assets</u>		
Cash and cash equivalents	320,485	\$321,078
Accounts receivable, net of allowance for doubtful accounts of \$5,671 December 31, 2008 and \$4,935 at June 30, 2008	185,733	192,200
Inventories, net (note 4)	143,064	158,251
Deferred income taxes	37,688	31,355
Income taxes receivable	2,098	17,115
Prepaid expenses and other current assets	17,325	19,241
Total current assets	706,393	739,240
<u>Non-current assets</u>		
Property, plant and equipment, net (note 6)	328,110	357,057
Goodwill (note 7)	211,320	234,647
Other intangibles (note 8)	36,495	46,771
Deferred income taxes	18,415	16,162
Other assets	2,351	7,508
Investment securities (note 3)	4,044	4,615
Total non-current assets	600,735	666,760
Total assets	\$1,307,128	\$1,406,000
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<u>Current liabilities</u>		
Accounts payable	\$54,456	\$56,308
Accrued expenses	53,942	61,338
Deferred revenue	20,918	26,133
Income taxes payable	25,593	3,799
Deferred income taxes	1,140	1,150
Current portion of long-term debt (note 9)	67,553	43,865
Total current liabilities	223,602	192,593
<u>Non-current liabilities</u>		
Deferred income taxes	14,683	18,333
Deferred revenue	16,064	15,673
Income taxes payable	3,856	3,837

Edgar Filing: RESMED INC - Form 10-Q

Long-term debt (note 9)	85,350	93,789
Total non-current liabilities	119,953	131,632
Total liabilities	343,555	324,225
Commitments and contingencies (notes 12 and 13)	-	-
<u>Stockholders' equity</u>		
Preferred Stock, \$0.01 par value, 2,000,000 shares authorized; none issued	-	-
Common stock, \$0.004 par value, 200,000,000 shares authorized; issued and outstanding 75,781,305 at December 31, 2008 and 75,975,031 at June 30, 2008 (excluding 5,584,247 and 4,875,618 shares held as treasury stock, respectively)	303	304
Additional paid-in capital	496,496	468,346
Retained earnings	610,222	548,343
Treasury stock, at cost	(169,042)	(142,987)
Accumulated other comprehensive income (note 5)	25,594	207,769
Total stockholders' equity	963,573	1,081,775
Total liabilities and stockholders' equity	\$1,307,128	\$1,406,000

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Income (Unaudited)

(In US\$ thousands, except share and per share data)

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Net revenues	\$222,980	\$202,679	\$440,911	\$388,419
Cost of sales	91,955	81,348	182,759	155,311
Gross profit	131,025	121,331	258,152	233,108
Operating expenses:				
Selling, general and administrative	70,086	67,644	141,424	130,527
Research and development	14,915	14,919	32,208	27,932
Amortization of acquired intangible assets	1,694	1,917	3,627	3,738
Donation to Foundation	1,000	-	1,000	-
Restructuring expenses (note 10)	-	18	-	2,314
Total operating expenses	87,695	84,498	178,259	164,511
Income from operations	43,330	36,833	79,893	68,597
Other income (expense), net:				
Interest income (expense), net	2,666	2,354	5,898	4,668
Other, net	985	(340)	(83)	(606)
Total other income (expense), net	3,651	2,014	5,815	4,062
Income before income taxes	46,981	38,847	85,708	72,659
Income taxes	13,128	11,986	23,829	21,673
Net income	\$33,853	\$26,861	\$61,879	\$50,986
Basic earnings per share	\$0.45	\$0.35	\$0.82	\$0.66
Diluted earnings per share (note 2-j)	\$0.44	\$0.34	\$0.80	\$0.65
Basic shares outstanding (000 s)	75,742	77,445	75,678	77,507
Diluted shares outstanding (000 s)	77,358	78,599	77,269	78,770

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In US\$ thousands)

	Six Months Ended	
	December 31, 2008	2007
<b>Cash flows from operating activities:</b>		
Net income	\$61,879	\$50,986
Adjustment to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	26,019	28,117
Stock-based compensation costs	12,422	9,819
Amortization of deferred borrowing costs	110	81
Provision for product warranties	1,010	1,139
Foreign currency revaluation	20,147	57
Write-down of cost-method investments	1,105	-
Tax benefit from stock option exercises	(1,440)	(2,797)
Changes in operating assets and liabilities, net of effect of acquisitions:		
Accounts receivable, net	(11,139)	1,929
Inventories, net	(7,012)	(3,659)
Prepaid expenses, net deferred income taxes and other current assets	(85)	(2,514)
Accounts payable, accrued expenses and other liabilities	21,383	(36,108)
<b>Net cash provided by operating activities</b>	<b>124,399</b>	<b>47,050</b>
<b>Cash flows from investing activities:</b>		
Purchases of property, plant and equipment	(61,861)	(40,294)
Capitalized interest	(1,201)	(557)
Patent registration costs	(2,268)	(2,938)
Purchases of foreign currency options	(710)	(318)
Business acquisitions	(322)	-
Proceeds from exercise of foreign currency options	814	-
Proceeds from disposal of business assets and contracts	1,441	-
Purchases of cost-method investment	(899)	-
Proceeds from sale of investment securities	-	16,450
Purchases of investment securities	-	(6,500)
<b>Net cash used in investing activities</b>	<b>(65,006)</b>	<b>(34,157)</b>
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of common stock, net	12,739	13,822
Proceeds from borrowing	71,000	15,000
Tax benefit from stock option exercises	1,440	2,797
Purchases of treasury stock	(28,977)	(24,559)

Edgar Filing: RESMED INC - Form 10-Q

Repayment of borrowings	(37,912)	(5,108)
Net cash provided by/(used in) financing activities	18,290	1,952
Effect of exchange rate changes on cash	(78,276)	5,866
Net (decrease)/increase in cash and cash equivalents	(593)	20,711
Cash and cash equivalents at beginning of period	321,078	257,792
Cash and cash equivalents at end of period	\$320,485	\$278,503
Supplemental disclosure of cash flow information:		
Income taxes paid/(received)	(\$148)	\$15,002
Interest paid	\$2,675	\$3,248
Goodwill on acquisition	\$322	\$876
Net acquisition costs accrued	-	(876)
Cash paid for acquisitions, including acquisition costs	\$322	\$-

See the accompanying notes to the unaudited condensed consolidated financial statements.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to the Condensed Consolidated Financial Statements**

**(Unaudited)**

(1) Organization and Basis of Presentation

ResMed Inc. (referred to herein as we, us, our or the Company) is a Delaware corporation formed in March 1994 holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia and Sweden.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2008 are not necessarily indicative of the results that may be expected for the year ending June 30, 2009.

The condensed consolidated financial statements for the three and six months ended December 31, 2008 and 2007 are unaudited and should be read in conjunction with the condensed consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2008.

(2) Summary of Significant Accounting Policies

(a) Basis of Consolidation

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from management's estimates.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(2) Summary of Significant Accounting Policies, Continued****(b) Revenue Recognition**

Revenue on product sales is generally recorded upon shipment, at which time title and risk of loss transfers to the customer. Revenue on product sales which require customer acceptance is not recorded until acceptance is received. Royalty revenue from license agreements is recorded when earned. Service revenue received in advance from service contracts is initially deferred and recognized ratably over the life of the service contract. Revenue received in advance from rental unit contracts is initially deferred and recognized ratably over the life of the rental contract. Revenue from sale of marketing or distribution rights is initially deferred and recognized ratably as revenue over the life of the contract. Freight charges billed to customers are included in revenue. All freight related expenses are charged to cost of sales. Taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, are reported on a net basis (excluded from revenue).

We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes we may provide upfront discounts for large orders, one time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. The costs of all such programs are recorded as an adjustment to revenue. Our products are predominantly therapy-based equipment and require no installation. As such, we have no significant installation obligations.

**(c) Cash and Cash Equivalents**

Cash equivalents include certificates of deposit, commercial paper and other highly liquid investments and are stated at cost, which approximates market. Investments with original maturities of 180 days or less are considered to be cash equivalents for purposes of the condensed consolidated statements of cash flows.

**(d) Inventories**

Inventories are stated at the lower of cost, determined principally by the first-in, first-out method, or net realizable value. We review and provide for any product obsolescence in our manufacturing and distribution operations with assessments of individual products and components (based on estimated future usage and sales) being performed throughout the year.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

(2) Summary of Significant Accounting Policies, Continued

(e) Property, Plant and Equipment

Property, plant and equipment, including rental equipment are recorded at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, generally two to ten years except for buildings, which are depreciated over an estimated useful life of 40 years. Straight-line and accelerated methods of depreciation are used for tax purposes. Maintenance and repairs are charged to expense as incurred.

We capitalize interest in connection with the construction of facilities. Actual construction costs incurred relating to facilities under active development qualify for interest capitalization. Interest capitalization ceases when the construction of a facility is complete and available for use. During the three months and six months ended December 31, 2008, we capitalized \$0.6 million and \$1.2 million, respectively, of interest relating to such construction costs. During the three months and six months ended December 31, 2007, we capitalized interest of \$0.4 and \$0.6 million, respectively.

(f) Intangible Assets

The registration costs for new patents are capitalized and amortized over the estimated useful life of the patent, generally five years. In the event of a patent being superseded, the unamortized costs are written off immediately.

Other intangible assets are amortized on a straight-line basis over their estimated useful lives, which range from seven to nine years. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairment of intangible assets has been identified during any of the periods presented.

(g) Goodwill

We conducted our annual review for goodwill impairment during the final quarter of fiscal 2008. In conducting our review of goodwill impairment, we identified reporting units, being components of our operating segment, as each of the entities acquired and giving rise to the goodwill. The fair value for each reporting unit was determined based on discounted cash flows and involved a two-step process as follows:

Step 1 - Compare the fair value for each reporting unit to its carrying value, including goodwill. For each reporting unit where the carrying value, including goodwill, exceeds the reporting unit's fair value, move on to step 2. If a reporting unit's fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.

- 8 -

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

(2) Summary of Significant Accounting Policies, Continued

(g) Goodwill (continued)

Step 2 - Allocate the fair value of the reporting unit to its identifiable tangible and non-goodwill intangible assets and liabilities. This will derive an implied fair value for the goodwill. Then, compare the implied fair value of the reporting unit's goodwill with the carrying amount of the reporting unit's goodwill. If the carrying amount of the reporting unit's goodwill is greater than the implied fair value of its goodwill, an impairment loss must be recognized for the excess.

The results of the review indicated that no impaired goodwill existed.

(h) Foreign Currency

The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than U.S. dollars, are translated into U.S. dollars for financial reporting purposes. Assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than U.S. dollars are translated at period-end exchange rates, and revenue and expense transactions are translated at average exchange rates for the period. Cumulative translation adjustments are recognized as part of comprehensive income, as described in Note 5, and are included in accumulated other comprehensive income in the condensed consolidated balance sheet until such time as the subsidiary is sold or substantially or completely liquidated. Gains and losses on transactions denominated in other than the functional currency of the entity are reflected in operations.

(i) Research and Development

All research and development costs are expensed in the period incurred.

(j) Earnings Per Share

We calculate earnings per share in accordance with Statement of Financial Accounting Standards No. 128, Earnings per Share (SFAS 128), as amended by SFAS No. 123(R), Share Based Payments (SFAS 123(R)), SFAS 128 requires the presentation of basic earnings per share and diluted earnings per share. Basic earnings per share is computed by

dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (2) Summary of Significant Accounting Policies, Continued

## (j) Earnings Per Share (continued)

The weighted average shares used to calculate basic earnings per share were 75,742,000 and 77,445,000 for the three months ended December 31, 2008 and 2007, respectively and were 75,678,000 and 77,507,000 for the six months ended December 31, 2008 and 2007. The difference between basic earnings per share and diluted earnings per share is attributable to the impact of outstanding stock options during the periods presented. Stock options had the effect of increasing the number of shares used in the calculation (by application of the treasury stock method) by 1,616,000 and 1,154,000 for the three months ended December 31, 2008 and 2007, respectively and 1,591,000 and 1,263,000 for the six months ended December 31, 2008 and 2007, respectively.

Stock options of 8,176,000 and 765,000 for the three months ended December 31, 2008 and 2007, respectively, and stock options of 14,016,000 and 1,257,000 for the six months ended December 31, 2008 and 2007, respectively, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive.

Basic and diluted earnings per share for the three months ended December 31, 2008 and 2007 and the six months ended December 31, 2008 and 2007 are calculated as follows (in thousands except per share data):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
<b>Numerator:</b>				
Net income, used in calculating diluted earnings per share	\$33,853	\$26,861	\$61,879	\$50,986
<b>Denominator:</b>				
Basic weighted-average common shares outstanding	75,742	77,445	75,678	77,507
<b>Effect of dilutive securities:</b>				
Stock options	1,616	1,154	1,591	1,263
Diluted weighted average shares	77,358	78,599	77,269	78,770
Basic earnings per share	\$0.45	\$0.35	\$0.82	\$0.66
Diluted earnings per share	\$0.44	\$0.34	\$0.80	\$0.65





---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

(2) Summary of Significant Accounting Policies, Continued

(k) Financial Instruments

The carrying value of financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt approximates the fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. Foreign currency option contracts are marked to market and therefore reflect their fair value. We do not hold or issue financial instruments for trading purposes. The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties.

(l) Foreign Exchange Risk Management

We enter into various types of foreign exchange contracts in managing our foreign exchange risk, including derivative financial instruments encompassing forward exchange contracts and foreign currency options.

The purpose of our foreign currency hedging activities is to protect us from adverse exchange rate fluctuations with respect to net cash movements resulting from the sales of products to foreign customers and our Australian manufacturing activities. We enter into foreign currency option contracts to hedge anticipated sales and manufacturing costs, principally denominated in Australian dollars, Euros and British Pounds Sterling. The terms of such foreign currency option contracts generally do not exceed three years.

Our foreign currency derivatives portfolio represents a cash flow hedge program against the net cash flow of our international manufacturing operations. We have determined our hedge program to be a non-effective hedge as defined under Statement of Financial Accounting Standards No. 133, *Accounting for Derivative Instruments and Hedging Activities*. The foreign currency derivatives portfolio is recorded in the condensed consolidated balance sheets at fair value and included in other assets or other liabilities.

All movements in the fair value of the foreign currency derivatives are recorded within other income, net in our condensed consolidated statements of income.

We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. The credit exposure of foreign exchange options at December 31, 2008 and June 30, 2008 was \$2.1 million and \$5.0 million, respectively, which represents the positive fair value of options held by us. These values are included in other

assets on the condensed consolidated balance sheets.

We held foreign currency option contracts with notional amounts totaling \$139.5 million and \$180.6 million at December 31, 2008 and June 30, 2008, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June 2010.

- 11 -

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(2) Summary of Significant Accounting Policies, Continued****(m) Income Taxes**

Income taxes are accounted for in accordance with SFAS No. 109 ( SFAS No. 109 ), Accounting for Income Taxes , which requires deferred tax assets and liabilities to be recognized using enacted tax rates for the effect of temporary differences between the financial statement and tax bases of recorded assets and liabilities. SFAS No. 109 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have determined that our future taxable income will be sufficient to recover our deferred tax assets, reported net of any valuation allowance. If in the future we determine that a change has occurred which will not allow this recovery, we will revise any valuation allowance against our deferred tax assets. This will result in a charge against our income tax provision.

The calculation of our effective tax rate is dependant upon the geographic composition of our world wide earnings, tax regulations governing each region and the availability of tax credits. In addition, the calculation of our tax liabilities involves uncertainties in the application of complex tax laws and regulations. We recognize these uncertainties based on FIN 48, Accounting for Uncertainty in Income Taxes . The final payment of the amounts regarding these uncertainties may ultimately prove to be less than or greater than our estimate. If this occurs there will be either a benefit or a charge to our income tax provision.

**(n) Investment Securities**

Management determines the appropriate classification of our investments in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. Debt securities for which we do not have the intent or ability to hold to maturity are classified as available-for-sale. Securities available-for-sale are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income.

At December 31, 2008 and June 30, 2008, the investments in debt securities are classified on the accompanying condensed consolidated balance sheet as investment securities.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(2) Summary of Significant Accounting Policies, Continued****(o) Warranty**

Estimated future warranty costs related to certain products are charged to operations in the period in which the related revenue is recognized. The liability for warranty costs is included in accrued expenses in our condensed consolidated balance sheets.

Changes in the liability for product warranty for the six months ended December 31, 2008 are as follows (in thousands):

Balance at July 1, 2008	\$6,863
Warranty accruals for the six months ended December 31, 2008	4,298
Warranty costs incurred for the six months ended December 31, 2008	(3,091)
Foreign currency translation adjustments	(1,574)
Balance at December 31, 2008	\$6,496

**(p) Impairment of Long-Lived Assets**

We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.

**(q) Cost-Method Investments**

The aggregate carrying amount of our cost-method investments at December 31, 2008 and June 30, 2008, was \$1.0 million and \$1.4 million, respectively. We review the carrying value of these investments at each balance sheet date and during the three months ended December 31, 2008 we recognized \$1.1 million of impairment losses. This was based on the determination that the impairment was other-than temporary due in part to the current uncertainty in the global financial markets and its impact on the wider economy. The written down investments include privately held service companies and research companies. The expense associated with this impairment has been included in the other income (expense) line within the consolidated statements of income. We have determined, subsequent to the impairment charge, that the carrying value of the investments do not exceed their estimated fair values.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (2) Summary of Significant Accounting Policies, Continued

## (r) Stock-Based Employee Compensation, Continued

We have granted stock options to personnel, including officers and directors, under our 2006 Incentive Award Plan, as amended (the 2006 Plan ) and the Amended and Restated ResMed Inc. 2006 Incentive Award Plan (the 2006 Amended Plan ). These options have expiration dates of seven years from the date of grant and vest over four years. We granted these options with the exercise price equal to the market value as determined at the date of grant. We have also offered to our personnel, including officers and directors, the right to purchase shares of our common stock at a discount under our employee stock purchase plan ( ESPP ).

In accordance with SFAS 123(R) we use the modified prospective method, which requires measurement of compensation expense of all stock-based awards at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Under this method, the provisions of SFAS 123(R) apply to all awards granted or modified after the date of adoption. In addition, the unrecognized expense of awards not yet vested at the date of adoption, determined under the original provisions of SFAS No. 123 shall be recognized in net income in the periods after adoption. The fair value of stock options is determined using the Black-Scholes valuation model. Such value is recognized as expense over the service period, using the graded-attribution method for stock-based awards granted prior to July 1, 2005 and the straight-line method for stock-based awards granted after July 1, 2005.

The fair value of stock options granted under our stock option plans and purchase rights granted under our ESPP is estimated on the date of the grant using the Black-Scholes valuation model, assuming no dividends and the following assumptions:

	Three months ended		Six months ended	
	December 31,		December 31,	
	2008	2007	2008	2007
Stock options:				
Weighted average grant date fair value	\$10.54	\$12.81	\$10.54 - \$11.04	\$12.81 - \$13.60
Weighted average risk-free interest rate	1.8%	3.8%	1.8 - 3.1%	3.2 - 4.6%
Expected option life in years	4.0 - 4.8	4.1 - 4.8	4.0 - 4.8	4.0 - 4.8

## Edgar Filing: RESMED INC - Form 10-Q

Expected volatility	34 - 38%	27 - 28%	27 - 38%	27 - 28%
ESPP purchase rights:				
Weighted average risk-free interest rate	5.0%	5.0%	5.0%	5.0%
Expected option life in years	6 months	6 months	6 months	6 months
Expected volatility	30%	30%	30%	30%

- 14 -



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (2) Summary of Significant Accounting Policies, Continued

## (r) Stock-Based Employee Compensation, Continued

Expected volatilities are based on a combination of historical volatilities of our stock and the implied volatilities from traded options of our stock corresponding to the expected term of the options. We use a combination of the historic and implied volatilities as we believe the addition of the implied volatility is more representative of our future stock price trends. While there is a tradeable market of options on our common stock less emphasis is placed on the implied volatility of these options due to the relative low volumes of these traded options and the difference in the terms compared to our employee options. The expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

## (3) Investment Securities

The estimated fair value of investment securities as of December 31, 2008 and June 30, 2008 are \$4.0 million and \$4.6 million, respectively. These investments are diversified among high credit quality investment grade securities in accordance with our investment policy. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

At December 31, 2008, our investment securities were held in Aaa rated auction securities with various maturities between July 2039 and November 2047. These investments had regular roll-over or auction dates at which time the interest rates were re-set or the investments were redeemed for cash. During the six months ended December 31, 2008, there were no auctions with respect to these investments due to the current liquidity issues surrounding the domestic and global capital markets. We continue to earn interest on these investments in accordance with the contract until the next auction occurs. During November 2008, we accepted an offer from UBS that gave us a right to sell our investment securities back to UBS at full par value after June 30, 2010. However, in the event we need to access the funds invested in these auction rate securities prior to June 30, 2010 we may not be able to liquidate these securities at the par value. Therefore given the current market liquidity conditions and our intention to hold these investments until the rights under the UBS offer can be exercised on June 30, 2010 we have reclassified these securities from current to non-current assets. We also believe the current lack of liquidity of these investments is temporary and have therefore recorded the excess of the carrying value of \$1.0 million over the fair value to comprehensive income within

stockholders equity. Additionally, based on our ability to access our cash and cash equivalents, expected operating cash flows, and other sources of cash, we do not anticipate the current lack of liquidity on these investments will affect our ability to operate the business in the ordinary course.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(4) Inventories**

Inventories were comprised of the following at December 31, 2008 and June 30, 2008 (in thousands):

	December 31, 2008	June 30, 2008
Raw materials	\$51,959	\$58,768
Work in progress	2,137	2,165
Finished goods	88,968	97,318
	\$143,064	\$158,251

**(5) Comprehensive Income**

The components of comprehensive income, net of tax, were as follows (in thousands):

	Three months ended December 31,		Six months ended December 31,	
	2008	2007	2008	2007
Net income	\$33,853	\$26,861	\$61,879	\$50,986
Foreign currency translation gains/(losses)	(52,627)	(1,573)	(181,605)	29,307
Unrealized loss on investment securities	(415)	-	(570)	-
Comprehensive (loss)/income	(\$19,189)	\$25,288	(\$120,296)	\$80,293

We do not provide for U.S. income taxes on foreign currency translation adjustments since we do not provide for such taxes on undistributed earnings of foreign subsidiaries.



**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(6) Property, Plant and Equipment**

Property, plant and equipment were comprised of the following as of December 31, 2008 and June 30, 2008 (in thousands):

	December 31, 2008	June 30, 2008
Machinery and equipment	\$71,351	\$83,543
Computer equipment	73,840	85,856
Furniture and fixtures	30,455	36,126
Vehicles	2,875	3,099
Clinical, demonstration and rental equipment	59,174	64,506
Leasehold improvements	19,157	22,609
Land	52,393	63,615
Buildings	126,795	169,076
Construction in Progress	73,345	37,073
	509,385	565,503
Accumulated depreciation and amortization	(181,275)	(208,446)
	\$328,110	\$357,057

**(7) Goodwill**

Changes in the carrying amount of goodwill for the six months ended December 31, 2008 were as follows (in thousands):

Balance at July 1, 2008	\$234,647
Foreign currency translation adjustments	(23,649)
Payment of earn-out relating to prior period business acquisition	322
Balance at December 31, 2008	\$211,320

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(8) Other Intangible Assets**

Other intangible assets are comprised of the following as of December 31, 2008 and June 30, 2008 (in thousands):

	December 31, 2008	June 30, 2008
Developed/core product technology	\$34,246	\$38,607
Accumulated amortization	(17,686)	(17,181)
Developed/core product technology, net of accumulated amortization	16,560	21,426
Trade names	1,817	2,049
Accumulated amortization	(938)	(912)
Trade names, net of accumulated amortization	879	1,137
Customer relationships	16,757	19,205
Accumulated amortization	(7,404)	(7,341)
Customer relationships, net of accumulated amortization	9,353	11,864
Patents	25,843	31,626
Accumulated amortization	(16,140)	(19,282)
Patents, net of accumulated amortization	9,703	12,344
Other intangibles, net of accumulated amortization	\$36,495	\$46,771

Intangible assets consist of patents, customer relationships, trade names and developed/core product technology and are amortized over the estimated useful life of the assets, generally between five and nine years. There are no expected residual values related to these intangible assets.

**(9) Long-Term Debt**

Long-term debt at December 31, 2008 and June 30, 2008 consists of the following (in thousands):

	December 31, 2008	June 30, 2008
Long-term loans	\$67,473	\$43,775
Capital lease	80	90
Current portion of long-term debt	\$67,553	\$43,865
Long-term loans	\$84,969	\$93,314
Capital lease	381	475
Non current portion of long-term debt	\$85,350	\$93,789

**Revolving Facility**

On March 13, 2006, our wholly owned subsidiaries ResMed Corp., ResMed Motor Technologies Inc. (formerly known as Servo Magnetics Inc.) and ResMed EAP Holdings Inc. entered into a Second Amended and Restated Revolving Loan Agreement with Union Bank of California, N.A. as administrative agent for the Lenders (the Loan Agreement), that provides for a revolving loan of up to \$65 million. Payment of principal must be made to reduce the total outstanding principal to \$55 million on March 1, 2009 and the entire outstanding principal amount must be repaid in full before March 1, 2011. The outstanding principal amount due under the loan will bear interest at a rate equal to LIBOR plus 0.75% to 1.00% (depending on the applicable leverage ratio). At December 31, 2008, there was \$55 million outstanding under this loan facility.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(9) Long-Term Debt, Continued**

The obligations of ResMed Corp., ResMed Motor Technologies Inc. and ResMed EAP Holdings Inc. under the Loan Agreement are secured by substantially all of the personal property of each of ResMed Corp., ResMed Motor Technologies Inc. and ResMed EAP Holdings Inc., and are guaranteed by ResMed Inc. under an Amended and Restated Continuing Guaranty and Pledge Agreement, which guaranty is secured by a pledge of the equity interests in ResMed Corp., ResMed Motor Technologies Inc. and ResMed EAP Holdings Inc. held by ResMed Inc. The Loan Agreement also contains customary covenants, including certain financial covenants and an obligation that ResMed Inc. maintain certain financial ratios, including a maximum ratio of total debt to EBITDA (as defined in the Loan Agreement), a fixed charge coverage ratio, a minimum tangible net worth, and a minimum ResMed Corp., ResMed Motor Technologies Inc. and ResMed EAP Holdings Inc. EBITDA and liquidity.

The entire principal amount of the revolving loan and any accrued but unpaid interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Loan Agreement. Events of default include, among other items, failure to make payments when due, the occurrence of a material default in the performance of any covenants in the Loan Agreement or related document or a 35% or more change in control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc. or ResMed EAP Holdings Inc. At December 31, 2008, we were in compliance with our debt covenants.

**Syndicated Facility**

On June 8, 2006, our wholly owned Australian subsidiary, ResMed Limited, entered into a Syndicated Facility Agreement with HSBC Bank Australia Limited as original financier, facility agent and security trustee, that provides for a loan in three tranches (the Syndicated Facility Agreement).

Tranche A is a Euro ( EUR ) 50 million five-year term loan facility that refinanced all amounts outstanding under a syndicated facility agreement dated May 16, 2005, between ResMed Limited and HSBC Bank Australia Limited, to fund the obligations of our wholly owned French subsidiary ResMed SAS under its agreement to acquire Saime SAS. Tranche A bears interest at a rate equal to LIBOR for deposits denominated in EUR plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and its subsidiaries (the ResMed Group) for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche A to EUR 37.75 million on June 30, 2008, EUR 27.5 million on June 30, 2009, EUR 15 million on December 31, 2009, and the entire outstanding principal amount must be repaid in full on June 8, 2011. At December 31, 2008, the Tranche A facility loan had an amount outstanding of EUR 27.5 million, equivalent to approximately U.S. dollars ( USD ) 38.4 million.





---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(9) Long-Term Debt, Continued**

Tranche B is a USD 15 million term loan facility that may only be used for the purpose of financing capital expenditures and other asset acquisitions by the ResMed Group. Tranche B bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars, USD or British Pounds Sterling plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire principal amount must be repaid in full on June 8, 2011. At December 31, 2008 there was \$9.0 million outstanding under this loan facility.

Tranche C is a USD 60 million term loan facility that may only be used for the purpose of the payment by ResMed Limited of a dividend to ResMed Holdings Limited, which will ultimately be paid to ResMed Inc. Tranche C bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars or USD plus a margin of 0.70% or 0.80%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire outstanding principal amount must be repaid in full by June 8, 2009. At December 31, 2008, there were no amounts outstanding under this loan facility.

Simultaneous with the Syndicated Facility Agreement, ResMed Limited entered into a working capital agreement with HSBC Bank Australia Limited for revolving, letter of credit and overdraft facilities up to a total commitment of 6.5 million Australian dollars, and ResMed (UK) Limited entered into a working capital agreement with HSBC Bank plc for a revolving cash advance facility for a total commitment of up to 3 million British Pounds Sterling. At December 31, 2008, there were no amounts outstanding under any of these arrangements.

**First Amended and Restated Syndicated Facility Agreement**

On September 30, 2008, our wholly-owned Australian subsidiary, ResMed Limited, agreed to amend and restate the Syndicated Facility Agreement entered into on June 8, 2006. The amended and restated agreement ( First Amended and Restated Syndicated Facility Agreement ) with the Hong Kong and Shanghai Banking Corporation, Sydney Branch as financier and HSBC Bank Australia Limited as facility agent and security trustee, provides for an additional Tranche D term loan facility in the amount of 50 million US dollars. The financier has the right to assign part or all of its rights and/or obligations under the First Amended and Restated Syndicated Facility Agreement to other financial institutions.

The additional \$50 million loan facility will be used for general corporate purposes. The additional loan facility bears interest at a rate equal to LIBOR for deposits denominated in US dollars, plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and subsidiaries for the most recently completed fiscal year

for the applicable interest period. The entire principal amount of the additional loan facility must be repaid in full by September 30, 2009. At December 31, 2008 there was \$50.0 million outstanding under this loan facility.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(9) Long-Term Debt, Continued**

The loan facility is secured by a pledge of one hundred percent of the shares of ResMed Inc.'s subsidiary, Saime SAS, pursuant to a pledge agreement. The Syndicated Facility Agreement also contains customary covenants, including certain financial covenants and an obligation that ResMed Limited maintains certain financial ratios, including a minimum debt service cover ratio, a maximum ratio of total debt to EBITDA and a minimum tangible net worth. The entire principal amount of the loan and any accrued, but unpaid, interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Syndicated Facility Agreement. Events of default include, among other items, failure to make payments when due, breaches of representations, warranties or covenants, the occurrence of certain insolvency events, the occurrence of an event or change which could have a material adverse effect on ResMed Limited and its subsidiaries, and if ResMed Inc. ceases to control ResMed Limited, ResMed Corp., ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited, Take Air Medical Handels-GmbH or Saime SAS.

The obligations of ResMed Limited under the loan facility are subject to two guarantee and indemnity agreements, one on behalf of ResMed Inc. and its U.S. subsidiary, ResMed Corp., and another on behalf of ResMed's international subsidiaries, ResMed SAS (other than Tranche C), ResMed GmbH & Co. KG, ResMed (UK) Limited and Take Air Medical Handels-GmbH. At December 31, 2008, we were in compliance with our debt covenants.

**Capital Lease**

As part of the acquisition of Saime SAS, we assumed a capital lease over land and buildings. This lease contains an option to purchase the property, for nominal consideration, at the end of the lease term in September 2014.

Details of contractual debt maturities at December 31, 2008 are as follows (in thousands):

	Total	2009	Payments Due by Period				
			2010	2011	2012	2013	Thereafter
Long-term debt	\$152,442	67,473	-	84,969	-	-	-
Capital leases	\$461	80	80	80	80	80	61
<b>Total</b>	<b>\$152,903</b>	<b>\$67,553</b>	<b>\$ 80</b>	<b>\$85,049</b>	<b>\$80</b>	<b>\$80</b>	<b>\$61</b>



**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(10) Restructuring Expenses**

No restructuring expenses were incurred during the three months and six months ended December 31, 2008. Restructuring expenses incurred during the three and six months ended December 31, 2007 were \$18,000 (\$15,000 net of tax) and \$2.3 million (\$1.8 million net of tax), respectively. Restructuring expenses consisted predominantly of expenses associated with our decision to streamline European management including the closure of part of the European headquarters in Basel, Switzerland and two regional offices in the Netherlands. This mainly comprised of employee termination costs, leasehold improvement write-downs and property lease exit costs.

Following is a summary of the restructuring liabilities related to the restructure of our European operations during the six months ended December 31, 2008 (in thousands):

	Accrued employee costs	Other accrued costs	Total accrued costs
Balance at July 1, 2008	\$97	\$98	\$195
Cash payments and asset write-downs	(97)	(98)	(195)
Balance at December 31, 2008	\$-	\$-	\$-

**(11) Stockholders Equity**

**Common Stock.** On June 6, 2002, the Board of Directors authorized us to repurchase up to 8.0 million shares of outstanding common stock. During the three months and six months ended December 31, 2008, we repurchased 0.1 and 0.7 million shares at a cost of \$2.0 million and \$26.1 million, respectively. At December 31, 2008, we have repurchased a total of 5.6 million shares at a cost of \$169.0 million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.

**Preferred Stock.** In April 1997, the Board of Directors authorized 2,000,000 shares of \$0.01 par value preferred stock. No such shares were issued or outstanding at June 30, 2008.

**Employee Stock Purchase Plan (the ESPP).** The ESPP was approved by our stockholders at the Annual General Meeting in November 2003. Under the ESPP, participants are offered the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the Board of Directors Compensation Committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value

of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than \$25,000 in common stock during any calendar year. On August 21, 2006, the Board of Directors approved a reduction in the number of shares available for grant under the ESPP to 500,000 shares, effective as of November 9, 2006, the date of the stockholder approval of the 2006 Plan. The number of securities remaining available for future issuance under the ESPP at December 31, 2008 is 193,000.

During the three months and six months ended December 31, 2008, we recognized \$0.4 million and \$0.8 million, respectively of stock-based compensation expense associated with the ESPP and issued 68,520 shares at a share price of \$29.97.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

(11) Stockholders Equity, Continued

**Stock Options.** We have granted stock options to personnel, including officers and directors, in accordance with the 2006 Plan and the 2006 Amended Plan, which was approved at the annual meeting of the stockholders of RedMed Inc. on November 20, 2008. These options have expiration dates of seven years from the date of grant and vest over four years. We have granted these options with an exercise price equal to the market value as determined at the date of grant.

The maximum number of shares of our common stock authorized for issuance under the 2006 Amended Plan is 9,900,000, an increase from 7,800,000 shares formerly authorized for issuance under the 2006 Plan. The number of securities remaining available for future issuance under the 2006 Amended Plan at December 31, 2008 is 2,866,000. The number of shares of our common stock available for issuance under the 2006 Amended Plan will be reduced by (i) two and four tenths (2.4) shares, an increase from two and one tenth (2.1) shares, for each one share of common stock delivered in settlement of any full-value award, which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2006 Amended Plan to any individual during any calendar year, may not exceed 1,500,000 shares of our common stock, an increase from 1,000,000 shares under the 2006 Plan.

At December 31, 2008, there was \$62.8 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.9 years. The aggregate intrinsic value of the options outstanding and the options exercisable at December 31, 2008 was \$67.8 million and \$53.0 million, respectively. The aggregate intrinsic value of the options exercised during the three months and six months ended December 31, 2008 was \$1.6 million and \$7.8 million respectively. The total fair value of options that vested during the three months and six months ended December 31, 2008 was \$14.9 million and \$16.7 million, respectively.

The following table summarizes option activity during the six months ended December 31, 2008:

Options	Weighted Average	Weighted Average
---------	---------------------	---------------------



Edgar Filing: RESMED INC - Form 10-Q

		Exercise Price	Remaining Term in Years
Outstanding at beginning of period	9,683,816	\$34.69	5.6
Granted	2,422,450	31.76	
Exercised	(424,260)	24.22	
Forfeited	(189,474)	42.41	
Outstanding at end of period	11,492,532	34.33	5.6
Exercise price range of granted options	\$31.04 - \$43.35		
Options exercisable at end of period	5,583,802	30.27	

- 23 -

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

**(12) Legal Actions and Contingencies**

In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not have a material adverse effect on our consolidated financial statements taken as a whole.

During September and October 2004, we began receiving tax assessment notices for the audit of one of our German subsidiaries by the German tax authorities for the years 1996 through 1998. Certain aspects of these assessment notices are being contested and appealed to the German tax authority office. As the outcome of the appeal cannot be predicted with certainty, any tax issues resolved in a manner not consistent with our expectations may require us to adjust our provision for income tax in the period of resolution.

In February 2007, the University of Sydney commenced legal action in the Federal Court of Australia against us, claiming breach of a license agreement and infringement of certain intellectual property. The claim has been amended to include an allegation of breach of confidentiality. The university is seeking various types of relief, including an injunction against manufacturing, supplying, offering for sale, selling or exporting certain mask devices, payment of license fees, damages or an account of profits, interest, costs and declaration of a constructive trust over and assignment of certain intellectual property. In October 2007, we filed a defense denying the university's claim, as well as a cross-claim against the university seeking an order for rectification of the contract and alleging the university violated the Australian Trade Practices Act. The matter is ongoing. We do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements.

**(13) Voluntary Product Recall Expenses**

On April 23, 2007, we initiated a worldwide voluntary recall of approximately 300,000 units of our S8 flow generators, manufactured between July 2004 and May 15, 2006, as there is a remote potential for a short circuit in the power supply connector. We have worked with our distribution partners globally to provide a replacement device to patients who have an affected S8 flow generator. The initial estimated cost of this action was \$59.7 million which was recognized as a charge to cost of sales in the consolidated statement of income during the year ended June 30, 2007. During the year ended June 30, 2008, the three months ended December 31, 2008 and the six months ended December 31, 2008 we also recognized additional charges of \$3.1 million, nil and \$0.2 million, respectively, due to an increase in return rates and consulting charges. These costs represented our best estimate of probable costs based on current available data and accounted for factors such as expected return rates for the affected units, unit replacement costs, legal, consulting, logistical and temporary contractor expenses directly associated with the recall. We expect negligible additional costs associated with the recall and at December 31, 2008 there is no remaining recall accrual.



**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(13) Voluntary Product Recall Expenses**

Following is a summary of the liabilities related to the voluntary product recall that were recorded during the six months ended December 31, 2008 (in thousands):

	Total accrued costs
Balance at July 1, 2008	\$1,028
Voluntary product recall expenses	227
Cash payments	(1,175)
Foreign currency translation	(80)
Balance December 31, 2008	\$-

**(14) Fair Value Measurements**

On July 1, 2008 we adopted the provisions of FASB Statement No. 157, Fair Value Measurements ( FAS 157 ) for financial assets and liabilities recognized on a recurring basis. In accordance with FASB Staff Position 157-2, Effective date of FASB Statement 157, we have deferred the applications of FAS 157 for our nonfinancial assets and liabilities until fiscal year 2010. FAS 157 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements for fair value measurements. The adoption of FAS 157 for financial assets and liabilities did not have a material impact on our consolidated financial statements.

In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. In accordance with FAS157, we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The hierarchies of inputs required by FAS157 are as follows:

Level 1: Input prices quoted in an active market for identical financial assets or liabilities;

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other

inputs that are observable or can be corroborated by observable market data

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market

- 25 -

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (14) Fair Value Measurements, Continued

The following table summarizes our financial assets and liabilities using the valuation input hierarchy (in thousands):

	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$320,485	\$-	\$-	\$320,485
Investment securities	-	4,044	-	4,044
Cost-method investments	-	-	1,002	1,002
Foreign currency options	-	2,113	-	2,113
	\$320,485	\$6,157	\$1,002	\$327,644

We determine the fair value of our financial assets as follows:

**Cash and cash equivalents** The valuation used for our cash and other money market funds are derived from quoted market prices due to their short term nature and there is an active market for these financial instruments.

**Investment securities** These securities represent our auction rate securities as described in Note 3. At December 31, 2008, we had investments totaling \$5.0 million at par value with an estimated fair value of \$4.0 million. The value of these securities are calculated by third party valuation models based on observable market prices and inputs including future cash flows, yields and spreads.

**Cost-method investments** These investments include our holdings in privately held service companies and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values which can be market supported and observable inputs including future cash flows.

**Foreign currency options** These financial instruments are valued using third party valuation models based on market observable inputs, including interest rate curves, on market spot currency prices, volatilities and credit risk.

The following table shows a reconciliation of the six months ended December 31, 2008 for fair value measurements using significant unobservable inputs (thousands):

Cost-Method Investments

Edgar Filing: RESMED INC - Form 10-Q

Balance at July 1, 2008	\$1,405
Purchases	899
Impairment of cost-method investment	(1,105)
Foreign currency translation	(197)
Balance at December 31, 2008	\$1,002

- 26 -

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations  
Special Note Regarding Forward-Looking Statements**

This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words believe, expect, anticipate, will continue, will, estimate, plan, future and other similar expressions in these statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding the development and approval of new products and product applications, market expansion, pending litigation and the development of new markets for our products, such as cardiovascular and stroke markets. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Such forward-looking statements reflect the views of our management at the time such statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our Annual Report on Form 10-K for the fiscal year ended June 30, 2008 and elsewhere in this report.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in social, economic, market, legal or regulatory circumstances, changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. Should any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in such forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Overview**

The following is an overview of our results of operations for the three and six months ended December 31, 2008. Management's discussion and analysis ( MD&A ) of financial condition and results of operations is intended to help the reader understand the results of operations and financial condition of Resmed Inc. MD&A is provided as a supplement to, and should be read in conjunction with selected financial data and consolidated financial statements and notes, included herein.

During the three and six months ended December 31, 2008 we continued our efforts in building awareness of the consequences of untreated SDB and to grow our business in this market. In our efforts we have attempted to raise awareness through market and clinical initiatives highlighting the increasing link between the potential effects SDB can have on cardiovascular diseases and Type 2 diabetes. In September 2008, the European Society of Cardiologists published guidelines for the treatment of acute and chronic heart failure. For the first time, the guidelines noted that patients with symptomatic heart failure frequently have sleep-related disorders (central or obstructive sleep apnea) and recommended treatment with Continuous Positive Airway Pressure, CPAP, for patients diagnosed with obstructive sleep apnea. Just three months earlier the International Diabetes Federation issued a consensus statement on sleep disordered breathing and Type 2 Diabetes, where the substantial value of identifying and treating diabetic patients suffering from sleep disordered breathing was also recognized and recommended. The increasing awareness among the co-morbidity specialists supports the efforts and investment we are making in new markets, including diabetes and cardiology.

We are committed to ongoing investment in research and development and product enhancements. During the three months and six months ended December 31, 2008 we invested \$14.9 million and \$32.2 million, respectively on research and development activities. Since the development of CPAP, we have developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Our new product release schedule remains active, particularly in both the mask and bilevel categories. We have introduced new masks in both Europe and the US during the second quarter of fiscal 2009, including the release of Swift LT for Her, which was the first nasal pillows product released that has been designed and marketed specifically for female patients. Additionally, during the six months ended December 31, 2008, we released a series of new bilevels in Europe and the VPAP IV in North and Latin America. These products utilize our patented EasyBreathe motor technology, providing performance at up to 90% less noise than other leading competitors.

During the quarter ended December 31, 2008, our net revenue increased by 10% when compared to the quarter ended December 31, 2007. These results were primarily driven by increasing unit sales of our flow generators, masks and accessories, including sales from our new VPAP IV bilevel flow generators and Swift LT nasal pillows. Gross margin was 59% for the quarter ended December 31, 2008 compared to 60% for the same period in fiscal 2007. For the

quarter ended December 31, 2008, we recognized acquisition related amortization expenses and stock-based compensation costs of \$1.7 million and \$6.8 million, respectively. Diluted earnings per share for the quarter ended December 31, 2008 increased to \$0.44 per share, up from \$0.34 per share in the quarter ended December 31, 2007.

Total operating cash flow for the quarter ended December 31, 2008, was \$56.5 million compared to \$16.9 million for the quarter ended December 31, 2007. At December 31, 2008, our cash and cash equivalents totaled \$320.5 million, our total assets were \$1.3 billion and our stockholders' equity was \$1.0 billion.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Net Revenue**

Net revenue increased for the three months ended December 31, 2008 to \$223.0 million compared to \$202.7 million for the three months ended December 31, 2007, an increase of \$20.3 million or 10%. The increase in net revenue is primarily attributable to an increase in unit sales of our flow generators, masks and accessories. Movements in international currencies against the U.S. dollar negatively impacted revenues by approximately \$11.1 million during the three months ended December 31, 2008. Excluding the impact of unfavorable foreign currency movements, net revenue for the three months ended December 31, 2008 increased by 16% compared to the three months ended December 31, 2007.

Net revenue in North and Latin America increased for the three months ended December 31, 2008 to \$123.1 million from \$100.2 million for the three months ended December 31, 2007, an increase of 23%. We believe this growth has been generated by increased public and physician awareness of sleep-disordered breathing and growth generated from our recent product releases including the S8II flow generator, VPAP IV bilevel flow generator, Swift LT nasal pillows mask and Mirage Quattro full-face mask. Net international revenue, which includes all markets outside North and Latin America, for the three months ended December 31, 2008 decreased to \$99.9 million from \$102.5 million compared to the three months ended December 31, 2007, a decrease of 3%. Movements in international currencies against the U.S. dollar negatively impacted international revenues by approximately \$11.1 million during the three months ended December 31, 2008. Excluding the impact of movements in international currencies, international sales grew by 8% compared to the three months ended December 31, 2007. This international sales growth predominantly reflects growth in the overall sleep-disordered breathing market and growth generated from our recent product releases including the S8II flow generator, VPAP IV bilevel flow generator and Mirage Quattro full-face mask.

Revenue from sales of flow generators, including humidifiers, for the three months ended December 31, 2008 totaled \$126.2 million, an increase of 9% compared to the three months ended December 31, 2007 of \$116.2 million, with an increase of 25% in North and Latin America offset by a decrease of 3% elsewhere. Revenue from sales of masks, motors and other accessories for the three months ended December 31, 2008 totaled \$96.8 million, an increase of 12% compared to the three months ended December 31, 2007 of \$86.5 million, including increases of 21% in North and Latin America offset by a decrease of 1% elsewhere. Excluding the impact of unfavorable currency movements international revenue increased by 8% and 10% for revenue of flow generators and masks, motors and other accessories, respectively for the three months ended December 31, 2008 compared to the three months ended December 31, 2007. We believe these increases primarily reflect growth in the overall sleep-disordered breathing market and contributions from new products.

The following table summarizes the percentage movements in our net revenue for the three months ended December 31, 2008 compared to the three months ended December 31, 2007:

Edgar Filing: RESMED INC - Form 10-Q

	North and Latin America	International	Total	International (Constant Currency) *	Total (Constant Currency)
Flow generators	25%	(3%)	9%	8%	15%
Masks, motors and other accessories	21%	(1%)	12%	10%	16%
Total	23%	(3%)	10%	8%	16%

\* Constant currency numbers exclude the impact of movements in international currencies.

- 29 -

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Net Revenue, continued**

Net revenue for the six months ended December 31, 2008, increased to \$440.9 million or 14% as compared to \$388.4 million for the six months ended December 31, 2007. For the six months ended December 31, 2008, revenue from sales of flow generators increased by 13% compared to the six months ended December 31, 2007; 19% in North and Latin America and 8% internationally. Revenue from sales of mask systems, motors and other accessories increased by 15%; 20% in North and Latin America and 6% internationally, for the six months ended December 31, 2008 compared to the six months ended December 31, 2007. Movement in international currencies against the U.S. dollar negatively impacted net revenue by approximately \$5.3 million during the six months ended December 31, 2008. Excluding the impact of unfavorable currency movements, total revenue for the six months ended December 31, 2008 increased by 15% compared to the six months ended December 31, 2007. We believe these increases primarily reflect growth in the overall sleep-disordered breathing market, and strong sales from our new products.

The following table summarizes the percentage movements in our net revenue for the six months ended December 31, 2008 compared to the six months ended December 31, 2007:

	North and Latin America	International	Total	International (Constant Currency) *	Total (Constant Currency)
Flow generators	19%	8%	13%	10%	14%
Masks, motors and other accessories	20%	6%	15%	9%	16%
Total	20%	7%	14%	10%	15%

\* Constant currency numbers exclude the impact of movements in international currencies.

**Gross Profit**

Gross profit increased for the three months ended December 31, 2008 to \$131.0 million from \$121.3 million for the three months ended December 31, 2007, an increase of \$9.7 million or 8%. Gross profit as a percentage of net revenue for the three months ended December 31, 2008 decreased to 59% from 60% for the three months ended December 31, 2007.

Gross profit increased for the six months ended December 31, 2008 to \$258.2 million from \$233.1 million for the six months ended December 31, 2007, an increase of \$25.1 million or 11%. Gross profit as a percentage of net revenue for the six months ended December 31, 2008 was 59% compared to 60% for the six months ended December 31, 2007.

The lower gross margin for the three and six months ended December 31, 2008 is primarily due to a general reduction in average selling prices partially offset by cost savings attributable to manufacturing and supply chain improvements and a favorable change in product mix as sales of our higher margin products represented a higher proportion of our sales.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Selling, General and Administrative Expenses**

Selling, general and administrative expenses increased for the quarter ended December 31, 2008 to \$70.1 million from \$67.6 million for the quarter ended December 31, 2007, an increase of 4%. Stock-based compensation expenses of \$5.7 million and \$4.5 million have been included within the selling, general and administration expenses for the three months ended December 31, 2008 and 2007, respectively. Selling, general and administrative expenses, as a percentage of net revenue, were 31% for the three months ended December 31, 2008 compared to 33% for the three months ended December 31, 2007.

Selling, general and administrative expenses increased for the six months ended December 31, 2008 to \$141.4 million from \$130.5 million for the six months ended December 31, 2007, an increase of \$10.9 million or 8%. Stock-based compensation expenses of \$10.5 million and \$8.4 million, have been included within the selling, general and administrative expenses for the six months ended December 31, 2008 and 2007, respectively. Selling, general and administrative expenses, as a percentage of net revenue, were 32% for the six months ended December 31, 2008 compared to 34% for the six months ended December 31, 2007.

The increase in selling, general and administrative expenses was primarily due to an increase in the number of sales and administrative personnel to support our growth and the increase in stock-based compensation. This increase in selling, general and administrative expenses was partly offset by the net depreciation of international currencies against the US dollar, which reduced our expenditure by approximately \$7.1 million and \$4.9 million for the three and six months ended December 31, 2008, respectively, as reported in U.S. dollars. As a percentage of net revenue, we expect our future selling, general and administrative expenses to continue in the range of 30% to 32%.

**Research and Development Expenses**

Research and development expenses for the three months ended December 31, 2008 at \$14.9 million, which is consistent with the three months ended December 31, 2007 of \$14.9 million. Stock-based compensation expenses of \$0.9 million and \$0.4 million have been included within research and development expenses for both the three months ended December 31, 2008 and 2007, respectively. Research and development expenses, as a percentage of net revenue, were 7% for the three months ended December 31, 2008, which is consistent with the 7% for the three months ended December 31, 2007.

Research and development expenses increased for the six months ended December 31, 2008 to \$32.2 million from \$27.9 million for the six months ended December 31, 2007, an increase of \$4.3 million or 15%. Stock-based compensation expenses of \$1.4 million and \$1.0 million have been included within research and development expenses for both the six months ended December 31, 2008 and 2007. Research and development expenses, as a percentage of net revenue, were 7%, for the six months ended December 31, 2008, which is consistent with the 7% for

the six months ended December 31, 2007.

The increase in research and development expenses was primarily due to an increase in charges for consulting fees and an increase in clinical trials, including the SERVE-HF study. The increase in research and development expenses was partly offset due to the net depreciation of international currencies against the U.S. dollar, which lowered our expenses by approximately \$4.0 million and \$3.5 million for the three and six months ended December 31, 2008, as reported in U.S. dollars. As a percentage of net revenue, we expect our future research and development expense to continue in the range of 6% to 7%.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Amortization of Acquired Intangible Assets**

Amortization of acquired intangible assets for the three months and six months ended December, 2008 totaled \$1.7 million and \$3.6 million, respectively, as compared to \$1.9 million and \$ 3.7 million for the three months ended December 31, 2007, respectively. The decrease in amortization expense is mainly attributable to the appreciation of the U.S. dollar against the Euro as the majority of the acquired intangible assets are denominated in Euros.

**Donations to Foundation**

During the three and six months ended December 31, 2008, we donated \$1.0 million to the ResMed Sleep Disordered Breathing Foundation. The Foundation was established primarily to promote research into the deleterious medical consequences of untreated sleep-disordered breathing. No donations were made during the three and six months ended December 31, 2007.

**Restructuring Expenses**

No restructuring expenses were incurred during the three months and six months ended December 31, 2008 compared to \$18,000 and \$2.3 million, respectively, for the three months and six months ended December 31, 2007. Restructuring expenses consisted of expenses associated with our decision to streamline European management, including the closure of part of the European headquarters in Basel, Switzerland and two regional offices in the Netherlands.

**Other Income (Expense), Net**

Other income for the three months ended December 31, 2008 was \$3.7 million, compared to \$2.0 million for the three months ended December 31, 2007. Other income (expense), net for the six months ended December 31, 2008 increased to \$5.8 million compared to \$4.1 million for the six months ended December 31, 2007. The increase in other income was predominantly due to higher interest income on additional cash balances and foreign currency gains but this was partly offset by a \$1.1 million impairment write-down of our at cost-method investments.

**Income Taxes**

Our effective income tax rate of approximately 27.9% for the three months ended December 31, 2008 was lower than our effective income tax rate of approximately 30.9% for the three months ended December 31, 2007, primarily due to a change in the geographic mix of taxable income.

Our effective income tax rate of approximately 27.8% for the six months ended December 31, 2008 was lower than

our effective tax rate of 29.8% for the six months ended December 31, 2007. The lower tax rate was primarily due to a change in the geographic mix of taxable income.

**Net Income**

As a result of the factors above, our net income for the three months ended December, 2008 was \$33.9 million or \$0.44 per diluted share compared to net income of \$26.9 million or \$0.34 per diluted share for the three months ended December 31, 2007.

As a result of the factors above, our net income for the six months ended December 31, 2008 was \$61.9 million or \$0.80 per diluted share compared to net income of \$51.0 million or \$0.65 per diluted share for the six months ended December 31, 2007.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources**

As of December 31, 2008 and June 30, 2008, we had cash and cash equivalents of \$320.5 million and \$321.1 million, respectively. Working capital was \$482.8 million and \$546.6 million at December 31, 2008 and June 30, 2008, respectively.

Inventories at December 31, 2008 decreased by \$23.3 million or 14% to \$143.1 million compared to December 31, 2007 inventories of \$166.4 million. The percentage decrease in inventories reflects improved working capital management and the impact of movements in foreign currency exchange rates, particularly the depreciation of the Australian dollar and Euro relative to the U.S. dollar.

Accounts receivable at December 31, 2008 were \$185.7 million, an increase of \$14.9 million or 9% over the December 31, 2007 accounts receivable balance of \$170.8 million. This increase was largely consistent with the 10% incremental increase in revenues for the three months ended December 31, 2008 compared to the three months ended December 31, 2007. Accounts receivable days outstanding of 76 days at December 31, 2008, increased by 1 day compared to the 75 days at December 31, 2007. Our allowance for doubtful accounts as a percentage of total accounts receivable at December 31, 2008 and June 30, 2008 was 3.0% and 2.5%, respectively. The credit quality of our customers remains consistent with our past experience.

During the six months ended December 31, 2008, we generated cash of \$124.4 million from operations. Movements in foreign currency exchange rates during the six months ended December 31, 2008 had the effect of decreasing our cash and cash equivalents by \$78.3 million, as reported in U.S. dollars. Capital expenditures for the six months ended December 31, 2008, and 2007 aggregated \$61.9 million and \$40.3 million, respectively. The capital expenditures for the six months ended December 31, 2008 primarily reflected the construction of our new corporate headquarters in San Diego, California, computer hardware and software, rental and loan equipment and the purchase of production tooling equipment and machinery. As a result of these capital expenditures, our balance sheet reflects net property, plant and equipment of approximately \$328.1 million at December 31, 2008.

We are currently developing new corporate headquarters at San Diego, California. To date we have incurred expenditures of \$73.3 million in relation to the construction of our new corporate headquarters and we estimate additional construction and fit-out costs of approximately \$30.5 million to complete the project. We expect to complete the project in the final quarter of fiscal 2009 and to fund the remaining project costs through a combination of cash on hand and operating cash flows.

Details of contractual obligations at December 31, 2008 are as follows:

Edgar Filing: RESMED INC - Form 10-Q

In \$000 s	Total	Payments Due by Period					
		Dec 31, 2009	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Thereafter
Long-Term Debt	\$152,442	67,473	-	84,969	-	-	-
Operating Leases	\$39,854	12,435	9,088	6,483	2,489	2,045	7,314
Capital Leases	\$461	80	80	80	80	80	61
Purchase Obligations	\$73,615	31,102	41,921	583	9	-	-
Total Contractual Obligations <sup>(A)</sup>	\$266,372	111,090	51,089	92,115	2,578	2,125	7,375

<sup>(A)</sup> The liabilities related to unrecognized tax benefits are not included in the above contractual obligations because the timing cannot be reliably estimated.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources, Continued**

Details of other commercial commitments as at December 31, 2008 are as follows:

In \$000 s	Total	Amount of Commitment Expiration Per Period					
		Dec 31, 2009	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Thereafter
Standby Letters of Credit	\$37	37	-	-	-	-	-
Guarantees*	\$90,006	1,336	858	84,321	22	-	3,469
Total Commercial Commitments	\$90,043	1,373	858	84,321	22	-	3,469

\* The above guarantees relate mainly to guarantees required as part of our debt facilities and requirements under contractual obligations with insurance companies transacting with our German subsidiaries.

**Revolving Facility**

On March 13, 2006, our wholly-owned subsidiaries ResMed Corp., ResMed Motor Technologies Inc. and ResMed EAP Holdings Inc. entered into a Second Amended and Restated Revolving Loan Agreement with Union Bank of California, N.A. as administrative agent for the Lenders (the "Loan Agreement"), that provides for a revolving loan of up to \$65 million. Payment of principal must be made to reduce the total outstanding principal to \$55 million on March 1, 2009; and the entire outstanding principal amount must be repaid in full before March 1, 2011. The outstanding principal amount due under the loan will bear interest at a rate equal to LIBOR plus 0.75% to 1.00% (depending on the applicable leverage ratio). The Loan Agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of total debt to EBITDA (as defined in the Loan Agreement), a fixed charge coverage ratio, a minimum tangible net worth, and that certain of our subsidiaries maintain a minimum EBITDA and liquidity. We are currently in compliance with all of these covenants. At December 31, 2008 there was \$55 million outstanding under this loan facility.

**Syndicated Facility**

On June 8, 2006, our wholly owned Australian subsidiary, ResMed Limited, entered into a Syndicated Facility Agreement with HSBC Bank Australia Limited as original financier, facility agent and security trustee, that provides for a loan in three tranches (the "Syndicated Facility Agreement").

Tranche A is a Euro (EUR) 50 million five-year term loan facility that refinanced all amounts outstanding under a syndicated facility agreement dated May 16, 2005, between ResMed Limited and HSBC Bank Australia Limited, to fund the obligations of our wholly owned French subsidiary ResMed SAS under its agreement to acquire Saime SAS.

Tranche A bears interest at a rate equal to LIBOR for deposits denominated in EUR plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and its subsidiaries (the ResMed Group ) for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche A to EUR 37.75 million on June 30, 2008, EUR 27.5 million on June 30, 2009, EUR 15 million on December 31, 2009, and the entire outstanding principal amount must be repaid in full on June 8, 2011. At December 31, 2008, the Tranche A facility loan had an amount outstanding of EUR 27.5 million, equivalent to approximately U.S. dollars ( USD ) 38.4 million.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources, Continued**

Tranche B is a USD 15 million term loan facility that may only be used for the purpose of financing capital expenditures and other asset acquisitions by the ResMed Group. Tranche B bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars, USD or British Pounds Sterling plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire principal amount must be repaid in full on June 8, 2011. At December 31, 2008, there was USD 9.0 million outstanding under this loan facility.

Tranche C is a USD 60 million term loan facility that may only be used for the purpose of the payment by ResMed Limited of a dividend to ResMed Holdings Limited, which will ultimately be paid to ResMed Inc. Tranche C bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars or USD plus a margin of 0.70% or 0.80%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire outstanding principal amount must be repaid in full by June 8, 2009. At December 31, 2008, there were no amounts outstanding under this loan facility.

Simultaneous with the Syndicated Facility Agreement, ResMed Limited entered into a working capital agreement with HSBC Bank Australia Limited for revolving, letter of credit and overdraft facilities up to a total commitment of 6.5 million Australian dollars, and ResMed (UK) Limited entered into a working capital agreement with HSBC Bank plc for a revolving cash advance facility for a total commitment of up to 3 million British Pounds Sterling. At December 31, 2008, there were no amounts outstanding under any of these arrangements.

**First Amended and Restated Syndicated Facility Agreement**

On September 30, 2008, our wholly-owned Australian subsidiary, ResMed Limited, agreed to amend and restate the Syndicated Facility Agreement entered into on June 8, 2006. The amended and restated agreement ( First Amended and Restated Syndicated Facility Agreement ) with the Hong Kong and Shanghai Banking Corporation, Sydney Branch as financier and HSBC Bank Australia Limited as facility agent and security trustee, provides for an additional Tranche D term loan facility in the amount of 50 million US dollars. The financier has the right to assign part or all of its rights and/or obligations under the First Amended and Restated Syndicated Facility Agreement to other financial institutions

The additional \$50 million loan facility will be used for general corporate purposes. The additional loan facility bears interest at a rate equal to LIBOR for deposits denominated in US dollars, plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and subsidiaries for the most recently completed fiscal year for the applicable interest period. The entire principal amount of the additional loan facility must be repaid in full by

September 30, 2009. At December 31, 2008, there was USD 50.0 million outstanding under this loan facility.

We expect to satisfy all of our short-term liquidity requirements through a combination of cash on hand, cash generated from operations and our \$8.9 million in undrawn facilities with HSBC.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Common stock**

On June 6, 2002, the Board of Directors authorized us to repurchase up to 8.0 million shares of outstanding common stock. During the three months and six months ended December 31, 2008, we repurchased 0.1 million and 0.7 million shares at a cost of \$2.0 million and \$26.1, million respectively. At December 31, 2008, we have repurchased a total of 5.6 million shares at a cost of \$169.0 million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.

**Critical Accounting Principles and Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements:

(1) Allowance for Doubtful Accounts. We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments, which results in bad debt expense. We determine the adequacy of this allowance by continually evaluating individual customer receivables, considering a customer's financial condition, credit history and current economic conditions. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

(2) Inventory Adjustments. Inventories are stated at lower of cost or market and are determined by the first-in, first-out method. We review the components of inventory on a regular basis for excess, obsolete and impaired inventory based on estimated future usage and sales. The likelihood of any material inventory write-downs is dependent on changes in competitive conditions, new product introductions by us or our competitors, or rapid changes in customer demand.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Critical Accounting Principles and Estimates, continued**

(3) Valuation of Goodwill, Intangible and Other Long-Lived Assets. We use assumptions in establishing the carrying value, fair value and estimated lives of our long-lived assets and goodwill. The criteria used for these evaluations include management's estimate of an asset's continuing ability to generate positive income from operations and positive cash flow in future periods compared to the carrying value of the asset, as well as the strategic significance of any identifiable intangible asset in our business objectives. If assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Useful lives and related amortization or depreciation expense are based on our estimate of the period that the assets will generate revenues or otherwise be used by us.

Factors that would influence the likelihood of a material change in our reported results include significant changes in the asset's ability to generate positive cash flow, loss of legal ownership or title to the asset, a significant decline in the economic and competitive environment on which the asset depends, significant changes in our strategic business objectives, utilization of the asset, and a significant change in the economic and/or political conditions in certain countries.

(4) Valuation of Deferred Income Taxes. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The likelihood of a material change in our expected realization of these assets is dependent on future taxable income, the intrinsic value of stock options, our ability to deduct tax loss carry forwards against future taxable income, the effectiveness of our tax planning strategies among the various tax jurisdictions that we operate in, and any significant changes in the tax treatment received on our business combinations.

(5) Provision for Warranty. We provide for the estimated cost of product warranties at the time the related revenue is recognized. The amount of this provision is determined by using a financial model, which takes into consideration actual, historical expenses and potential risks associated with our different products. This financial model is then used to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, revisions to our estimated warranty provision would be required.

(6) Revenue Recognition. Revenue on product sales is recorded at the time of shipment, at which time title transfers to the customer. Revenue on product sales, which require customer acceptance, is not recorded until acceptance is received. Royalty revenue from license agreements is recorded when earned. Service revenue received in advance

from service contracts is initially deferred and recognized ratably over the life of the service contract. Revenue received in advance from rental unit contracts is initially deferred and recognized ratably over the life of the rental contract. Revenue from sale of marketing and distribution rights is initially deferred and recognized ratably as revenue over the life of the contract. Freight charges billed to customers are included in revenue. All freight-related expenses are charged to cost of sales.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Critical Accounting Principles and Estimates, continued**

We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. As part of our sales processes we may provide upfront discounts for large orders, one time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. The costs of all such programs are recorded as an adjustment to revenue. Our products are predominantly therapy-based equipment and require no installation. As such, we have no significant installation obligations.

(7) Stock-Based Compensation. In accordance with SFAS No.123(R), we measure the compensation of all stock-based awards at fair value on date of grant. Such value is recognized as compensation expense over the service period, net of estimated forfeitures. We estimate the fair value of employee stock options using a Black-Scholes valuation model. The fair value of an award is affected by our stock price on the date of grant as well as other assumptions including the estimated volatility of our stock price over the term of the awards and the estimated period of time that we expect employees to hold their stock options. The risk-free interest rate assumption we use is based upon U.S. Treasury yield curve appropriate for the expected life of the awards. Expected volatilities are based on a combination of historical volatilities of our stock and the implied volatilities from traded options of our stock corresponding to the expected term of the options. We use a combination of the historic and implied volatilities as we believe the addition of the implied volatility is more representative of our future stock price trends. In order to determine the estimated period of time that we expect employees to hold their stock options, we have used historical rates by employee groups. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results differ from our estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. The aforementioned inputs entered into the option valuation model we use to fair value our stock awards are subjective estimates and changes to these estimates will cause the fair value of our stock awards and related stock-based compensation expense we record to vary.

(8) Income Tax. We have adopted the provisions of Financial Accounting Standards Board (FASB) Interpretation No. 48 Accounting for Uncertainty in Income Taxes An Interpretation of FASB Statement No. 109 ( FIN 48 ) on July 1, 2007. In accordance with FIN 48 we assess our income tax positions and record tax benefits for all years subject to examination based upon management's evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, we have recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.



---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Recently Issued Accounting Pronouncements**

In September 2006, the FASB issued FASB No. 157, Fair Value Measurements ( FASB 157 ), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. FASB 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. In February 2008, the FASB issued FASB Staff Position 157-2, Effective Date of FASB Statement 157 ( FSP 157-2 ), which delays the effective date of FAS 157 for all nonfinancial assets and nonfinancial liabilities, except those items which are recognized or disclosed at fair value in the financial statements on a recurring basis. We adopted this standard on July 1, 2008 and it did not have a material impact on our financial statements.

In February 2007, FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities ( SFAS 159 ), which allows entities to account for most financial instruments at fair value rather than under other applicable generally accepted accounting principles (GAAP), such as historical cost. The accounting results in the instrument being marked to fair value every reporting period with the gain or loss from a change in fair value recorded in the income statement. SFAS 159 is effective for financial statements issued for fiscal years beginning after November 15, 2007. Based upon our analysis and implementation of SFAS 159 as it relates to our balance sheet accounts, we did not elect the fair value option permitted in SFAS 159 for any of our eligible financial assets or liabilities. Therefore, SFAS 159 did not have any impact on our unaudited condensed consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised), Business Combinations ( SFAS No. 141(R) ). Under the requirements of SFAS No. 141(R), the acquiring entity will be required to recognize all assets and liabilities acquired in a transaction at their acquisition date fair value. SFAS No. 141(R) will also change the accounting treatment for specific transactions such as the recognition of contingent liabilities, the recognition of capitalized in-process research and development, restructuring costs, the treatment of acquisition related transaction costs and changes in the income tax valuation allowances. SFAS No. 141(R) is effective for business combinations for which the acquisition date is on or after July 1, 2009, with early adoption prohibited. The adoption of this standard will not impact our current financial statements but we are assessing the potential impact that the adoption of this standard will have on our future financial statements.

In December 2007, the FASB issued SFAS No. 160, Non-controlling Interests in Consolidated Financial Statements An amendment of ARB No.51 ( SFAS No. 160 ). SFAS No. 160 outlines the accounting and reporting requirements for non-controlling interests in consolidated financial statements such as recognizing non-controlling interests as a component of consolidated stockholder's equity separate from the parent equity and net income attributable to non-controlling interests be identified and shown separately on the face of the consolidated income statement. SFAS No. 160 also revises the accounting for increases and decreases in a parent's controlling interest. SFAS No. 160 is

effective for fiscal years and interim periods within those years, beginning after December 15, 2008, with early adoption prohibited. We do not believe the adoption of this standard will have a material impact on our financial statements.



**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES**

**Recently Issued Accounting Pronouncements, continued**

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities an Amendment of FASB Statement 133 ( SFAS No. 161 ). SFAS No. 161 requires disclosure of how and why an entity uses derivative instruments, how derivative instruments and related hedged items are accounted for and how derivative instruments and related hedged items affect an entity s financial position, financial performance and cash flows. SFAS No. 161 is effective for fiscal years and interim periods within those years, beginning after November 15, 2008. We do not believe the adoption of this standard will have a material impact on our financial statements.

**Off-Balance Sheet Arrangements**

As of December 31, 2008, we are not involved in any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

---

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures about Market Risk****Item 3. Quantitative and Qualitative Disclosures About Market Risk  
Interest Rate Risk**

We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents, investment securities and debt. At December 31, 2008, we maintain cash and cash equivalents of \$320.5 million containing financial instruments that have original maturities of less than twelve months. These financial instruments principally comprised of bank term deposits and at call accounts are invested at both short term fixed interest rates and variable interest rates. At December 31, 2008, we had total long-term debt, including the current portion of those obligations, of \$152.9 million. All of this debt is subject to variable interest rates. A hypothetical 10% change in interest rates during the three months ended December 31, 2008, would not have had a material impact on pretax income. We have no interest rate hedging agreements.

**Foreign Currency Market Risk**

Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian dollar. We have significant foreign currency exposure through both our Australian manufacturing activities and international sales operations.

We have established a foreign currency hedging program using purchased currency options to hedge foreign-currency-denominated financial assets, liabilities and manufacturing expenditures. The goal of this hedging program is to economically guarantee or lock in the exchange rates on our foreign currency exposures denominated in Euros and Australian dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes.

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures about Market Risk****Foreign Currency Market Risk, continued**

The table below provides information in U.S. dollar equivalents on our foreign-currency-denominated financial assets at December 31, 2008 (in thousands):

	Foreign Currency Financial Assets										
	Australian Dollar (AUD)	US Dollar (USD)	Euro (EUR)	Great Britain Pound (GBP)	Canadian Dollar (CAD)	Singapore Dollar (SGD)	New Zealand Dollar (NZD)	Swedish Krona (SEK)	Swiss Franc (CHF)	Sth African Rand (ZAR)	Norwegian Kroner (NOK)
<b>AUD Functional</b>											
Currency Entities:											
Assets		91,766	64,307	4,117	-	1,160	994	1,825	1,670	-	841
Liability		(87,469)	(45,852)	(328)	-	(247)	(161)	-	(23)	-	(111)
Net Total		4,297	18,455	3,789	-	913	833	1,825	1,647	-	730
<b>USD Functional</b>											
Currency Entities:											
Assets	-	-	-	-	2,520	-	-	-	-	-	-
Liability	-	-	-	-	-	-	-	-	-	-	-
Net Total	-	-	-	-	2,520	-	-	-	-	-	-
<b>EURO Functional</b>											
Currency Entities:											
Assets	-	1	-	-	-	-	-	-	-	-	-
Liability	-	(102)	-	(888)	-	-	-	(65)	-	-	(8)
Net Total	-	(101)	-	(888)	-	-	-	(65)	-	-	(8)
<b>GBP Functional</b>											
Currency Entities:											
Assets	-	715	10,546	-	-	-	-	-	-	511	-
Liability	-	(22)	(11,082)	-	-	-	-	(417)	-	-	(109)
Net Total	-	693	(536)	-	-	-	-	(417)	-	511	(109)
<b>CHF Functional</b>											
Currency Entities:											
Assets	-	202	2	3	-	-	-	-	-	-	-
Liability	-	(3)	(221)	(32)	-	-	-	-	-	-	-
Net Total	-	199	(219)	(29)	-	-	-	-	-	-	-
<b>MYR Functional</b>											
Currency Entities:											
Assets	461	28	60	11	-	-	-	-	-	-	-
Liability	-	-	-	-	-	-	-	-	-	-	-
Net Total	461	28	60	11	-	-	-	-	-	-	-
<b>NOK Functional</b>											
Currency Entities:											
Assets	-	-	-	-	-	-	-	-	-	-	-
Liability	-	(68)	(195)	(85)	-	-	-	(8)	(17)	-	-
Net Total	-	(68)	(195)	(85)	-	-	-	(8)	(17)	-	-
<b>SEK Functional</b>											

Edgar Filing: RESMED INC - Form 10-Q

Currency Entities:											
Assets	-	-	-	-	-	-	-	-	-	-	-
Liability	-	(113)	(43)	(17)	-	-	-	-	-	-	(20)
Net Total	-	(113)	(43)	(17)	-	-	-	-	-	-	(20)

- 42 -

**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures about Market Risk****Foreign Currency Market Risk, continued**

The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options held at December 31, 2008. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments. These notional amounts generally are used to calculate payments to be exchanged under our option contracts.

(In thousands except exchange rates)				Fair Value Assets/(Liabilities)	
Foreign Exchange Call Options	FY 2009	FY 2010	Total	Dec 31, 2008	June 30, 2008
<b>Receive AUD/Pay USD</b>					
Option amount	\$26,000	\$74,000	\$100,000	\$1,560	\$4,493
Ave. contractual exchange rate	AUD 1 = USD 0.8804	AUD 1 = USD 0.8493	AUD 1 = USD 0.8571		
<b>Receive AUD/Pay Euro</b>					
Option amount	\$4,194	\$26,558	\$30,752	\$302	\$381
Ave. contractual exchange rate	AUD 1 = Euro 0.6685	AUD 1 = Euro 0.5835	AUD 1 = Euro 0.5938		
<b>Receive AUD/Pay GBP</b>					
Option Amount	\$6,592	\$2,197	\$8,789	\$251	\$143
Ave. contractual exchange rate	AUD 1 = GBP 0.4912	AUD 1 = GBP 0.5120	AUD 1 = GBP 0.4962		

**Credit Market Risk**

At December 31, 2008, we held a number of investment securities in Aaa rated auction securities with various maturities between July 2039 and November 2047. These investments had regular roll-over or auction dates at which time the interest rates were re-set or the investments were redeemed for cash. During the three months and six months ended December 31, 2008, there were failed auctions with respect to these investments due to the current liquidity issues surrounding the domestic and global capital markets. During November 2008, we accepted an offer from UBS that gave us a right to sell our investment securities back to UBS at full par value after June 30, 2010. However, in the event we need to access the funds invested in these auction rate securities prior to June 30, 2010 we may not be able to liquidate these securities at the par value. Therefore given the current market liquidity conditions and our intention to hold these investments until the rights under the UBS offer can be exercised on June 30, 2010 we have reclassified these securities from current to non-current assets. We also believe the current lack of liquidity of these investments is temporary and have therefore recorded the excess of the carrying value over the fair value to comprehensive income within stockholders equity. Additionally, based on our ability to access our cash and cash equivalents, expected operating cash flows, and other sources of cash, we do not anticipate the current lack of liquidity on these investments will affect our ability to operate the business in the ordinary course.



**Table of Contents**

PART I - FINANCIAL INFORMATION

Item 4

**RESMED INC. AND SUBSIDIARIES**

**Item 4. Controls and Procedures**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2008.

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

**Table of Contents**

PART II - OTHER INFORMATION

Items 1-6

**RESMED INC. AND SUBSIDIARIES****PART II OTHER INFORMATION****Item 1 Legal Proceedings**

The information required by this Item is incorporated herein by reference to Note 12, Legal Actions and Contingencies, to the unaudited condensed consolidated financial statements under Part I, Item 1 of this report.

**Item 1A Risk Factors**

The discussion of our business and operations should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2008, which was filed with the SEC and describes the various risks and uncertainties to which we are or may become subject. At December 31, 2008, there have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended June 30, 2008 with the exception of the following:

**Our results of operations may be materially affected by global economic conditions generally, including conditions in the financial markets.** Recently, concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, the U.S. mortgage market and a declining residential real estate market in the U.S. have contributed to increased volatility and diminished expectations for the economy and the financial markets going forward. These factors, combined with volatile oil prices, declining business and consumer confidence and increased unemployment, have precipitated an economic slowdown and fears of a possible recession. It is difficult to predict how long the current economic conditions will continue and whether the economic conditions will continue to deteriorate. If the economic climate in the U.S. or outside the US continues to deteriorate or there is a shift in government spending priorities, customers or potential customers could reduce or delay their purchases, which could impact our revenue, our ability to manage inventory levels, collect customer receivables, and ultimately decrease our profitability.

**Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

Purchases of equity securities. The following table summarizes purchases by us of our common stock during the six months ended December 31, 2008:

Period 2008	Total Number of Shares	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs <sup>(1)</sup>	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs <sup>(1)</sup>
-------------	------------------------	------------------------------	---	---



Edgar Filing: RESMED INC - Form 10-Q

July 1 to July 31	622,500	36.87	622,500	(622,500)
August 1 to August 31	30,100	37.89	30,100	(30,100)
September 1 to September 30	-	-	-	-
October 1 to October 31	-	-	-	-
November 1 to November 30	-	-	-	-
December 1 to December 31	55,989	35.02	55,989	(55,989)
Total	708,589	36.77	708,589	2,415,793

- <sup>(1)</sup> On June 6, 2002, the Board of Directors authorized us to repurchase up to 8.0 million shares of our outstanding common stock. For the six months ended December 31, 2008 and 2007, we repurchased 708,589 and 612,600 shares at a cost of \$26.1 million and \$24.6 million, respectively. Since the inception of the share buyback program, we have repurchased 5,584,207 shares at a cost of \$169.0 million.

- 45 -

**Table of Contents**

PART II - OTHER INFORMATION

Items 1-6

**RESMED INC. AND SUBSIDIARIES****Item 3 Defaults Upon Senior Securities**

None

**Item 4 Submission of Matters to a Vote of Security Holders**

The Company's Annual Meeting of Stockholders was held on November 20, 2008. The holders of 63,341,314 shares of the Company's stock (approximately 84% of the outstanding shares) were present at the meeting in person or by proxy. The matters voted upon at the meeting were (1) to elect two directors, each to serve for a three-year term, (2) to ratify the selection of auditors of the Company for the fiscal year ending June 30, 2008 and (3) Approve the amended and restated 2006 Incentive Award Plan.

- (1) Christopher G. Roberts and John Wareham, each nominated by the Company's Board of Directors, were elected to serve until 2011. There were no other nominees. Shares were voted as follows:

Name	For	Withholding Vote For
Christopher G. Roberts	46,971,007	16,367,829
John Wareham	62,229,846	1,108,990

- (2) The amended and restated 2006 Incentive Award Plan for the 2009 fiscal year was approved and ratified: affirmative votes, 37,272,524 shares; negative votes 20,928,172, withholding vote for: 5,140,618.
- (3) The selection of KPMG LLP as independent public accountants for the 2008 fiscal year was ratified: affirmative votes, 62,867,081 shares; negative votes 453,022, withholding vote for: 21,211.

**Item 5 Other Information**

None

**Table of Contents**

PART II - OTHER INFORMATION

Items 1-6

**RESMED INC. AND SUBSIDIARIES**

**Item 6 Exhibits**

Exhibits (numbered in accordance with Item 601 of Regulation S-K)

- 3.1 First Restated Certificate of Incorporation of ResMed Inc. <sup>(1)</sup>
- 3.2 Fourth Amended and Restated Bylaws of ResMed Inc. <sup>(2)</sup>
- 10.1 First Amended and Restated Revolving Loan Agreement dated September 30, 2008 <sup>(3)</sup>
- 10.2 Amended and Restated 2006 Incentive Award Plan dated November 20, 2008 <sup>(4)</sup>
- 10.3 Departure of Directors or Certain Officers dated December 12, 2008 <sup>(5)</sup>
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1) Incorporated by reference to Exhibit 3.1 to the Registrants Annual Report on Form 10-K for the Fiscal Year ended June 30, 2007.  
 (2) Incorporated by reference to Exhibit 3.1 to the Registrants Current Report on Form 8-K filed on December 14, 2007.  
 (3) Incorporated by reference to Exhibit 10.1 to the Registrants Current Report on Form 8-K filed on October 6, 2008.  
 (4) Incorporated by reference to Exhibit 10.1 to the Registrants Current Report on Form 8-K filed on November 26, 2008.  
 (5) Incorporated by reference to Exhibit 10.1 to the Registrants Current Report on Form 8-K filed on December 15, 2008.

**Table of Contents**

PART II - OTHER INFORMATION

SIGNATURES

**RESMED INC. AND SUBSIDIARIES**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

February 6, 2009

ResMed Inc.

/s/ **KIERAN T. GALLAHUE**

Kieran T. Gallahue  
Chief Executive Officer

/s/ **BRETT A. SANDERCOCK**

Brett A. Sandercock  
Chief Financial Officer

- 48 -